ASAmna Mbbs Soulat

Amna Mbbs Soulat

*This is an algorithmically generated author record based on publicly available information.

Amna Mbbs Soulat has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exploring the association between atrial fibrillation and celiac disease: a comprehensive review

    by Rasish Mbbs Subedi, Amna Mbbs Soulat, Samia Mbbs Rauf Butt, Anmol Mbbs Mohan, Muhammad Mbbs Danish Butt, Suneel Mbbs Arwani, Gulzar Mbbs Ahmed, Koushik Mbbs Majumder, Priyanka Mbbs Mohan Lal, Vikash Kumar, et al.

    Objective: This paper aims to provide a comprehensive overview of the pathophysiology of atrial fibrillation (AF) and celiac disease (CD) individually while also exploring the emerging evidence of a potential association between the two conditions. Methods: The pathophysiology of AF, the most prevalent arrhythmia globally, and CD, an autoimmune condition triggered by gluten consumption, is examined. Genetic, structural, electrophysiological, and inflammatory factors contributing to their development are explored. Results: AF involves irregular atrial activity leading to electrical and structural remodeling of the atrium. CD is characterized by an immune response to gluten, primarily associated with HLA-DQ2 and HLA-DQ8 genetic mutations, resulting in damage to intestinal tissue. Emerging research suggests a link between AF and CD, possibly mediated through inflammation, fibrosis, and electromechanical delays in the atrium. Conclusion: Understanding the association between AF and CD carries significant clinical implications. Recognition of this relationship can assist in identifying individuals at higher risk for AF and inform proactive management strategies. Additionally, it underscores the importance of comprehensive care for CD patients, considering potential cardiac implications. Further research is warranted to elucidate precise mechanisms and explore potential therapeutic interventions targeting common pathways, opening avenues for enhanced patient care and future investigations.

  • Open Access

    MicroRNAs as promising biomarkers and potential therapeutic agents in breast cancer management: a comprehensive review

    by Priyanka Mbbs Mohan Lal, Muhammad Mbbs Hamza Siddiqui, Amna Mbbs Soulat, Anmol Mbbs Mohan, Dev Mbbs Tanush, Komal Mbbs Tirath, Sandesh Mbbs Raja, Muhammad Mbbs Khuzzaim Khan, Adarsh Mbbs Raja, Aayush Mbbs Chaulagain, et al.

    Breast cancer (BC), a complex and varied ailment, poses a significant global health burden. MicroRNAs (miRNAs) have emerged as vital regulators in BC progression, with potential implications for diagnosis and treatment. This review aims to synthesize current insights into miRNA dysregulation in BC. MiRNAs, small RNA molecules, govern gene expression post-transcriptionally and are implicated in BC initiation, metastasis, and therapy resistance. Differential expression of specific miRNAs in BC tissues versus normal breast tissue sheds light on underlying molecular mechanisms. MiRNAs also offer promise as diagnostic biomarkers due to their stable nature, accessibility in bodily fluids, and altered expression patterns in early-stage disease, augmenting conventional diagnostic methods. Beyond diagnosis, miRNAs also hold promise as therapeutic targets in BC. By modulating the expression of specific dysregulated miRNAs, it may be possible to restore normal cellular functions and overcome treatment resistance. However, several challenges need to be addressed before miRNA-based therapies can be translated into clinical practice, including the development of efficient delivery systems and rigorous evaluation through preclinical and clinical trials. MiRNAs represent a promising avenue in BC research, offering potential applications in diagnosis, prognosis, and therapeutic interventions. As our understanding of miRNA biology deepens and technology advances, further research and collaborative efforts are needed to fully exploit the diagnostic and therapeutic potential of miRNAs in BC management. Ultimately, the integration of miRNA-based approaches into clinical practice may lead to more personalized and effective strategies for combating this devastating disease.


  • Open Access

    Impact of artificial intelligence on the diagnosis, treatment and prognosis of endometrial cancer

    by Samia Rauf Mbbs Butt, Amna Mbbs Soulat, Priyanka Mohan Mbbs Lal, Hajar Fakhor, Siddharth Kumar Patel, Mashal Binte Mbbs Ali, Suneel Mcps Arwani, Anmol Mbbs Mohan, Koushik Mbbs Majumder, Vikash Kumar, et al.

    Endometrial cancer is one of the most prevalent tumours in females and holds an 83% survival rate within 5 years of diagnosis. Hypoestrogenism is a major risk factor for the development of endometrial carcinoma (EC) therefore two major types are derived, type 1 being oestrogen-dependent and type 2 being oestrogen independent. Surgery, chemotherapeutic drugs, and radiation therapy are only a few of the treatment options for EC. Treatment of gynaecologic malignancies greatly depends on diagnosis or prognostic prediction. Diagnostic imaging data and clinical course prediction are the two core pillars of artificial intelligence (AI) applications. One of the most popular imaging techniques for spotting preoperative endometrial cancer is MRI, although this technique can only produce qualitative data. When used to classify patients, AI improves the effectiveness of visual feature extraction. In general, AI has the potential to enhance the precision and effectiveness of endometrial cancer diagnosis and therapy. This review aims to highlight the current status of applications of AI in endometrial cancer and provide a comprehensive understanding of how recent advancements in AI have assisted clinicians in making better diagnosis and improving prognosis of endometrial cancer. Still, additional study is required to comprehend its strengths and limits fully.